The American Journal of Managed Care6d
Zongertinib Offers “The Best Toxicity Profile I Have Ever Seen,” Santos Says
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Targeted Oncology3d
Primary Progressive Disease Rate Supports IO/TKI Use in Frontline mRCC
Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...
Cure Today27d
FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC
The trials reported tumor shrinkage in 89% of TKI-naive and 56% of TKI-pretreated patients, with prolonged progression-free survival. Taletrectinib has a favorable safety profile and addresses unmet ...
The Victoria Advocate15d
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
The safety profile aligned with other EGFR-targeting ... Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights, approved by the China's NMPA for the treatment ...